[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"circadian-rhythm-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:circadian-rhythm-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,54,85,113,140,162,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100626690","mind-after-midnight-100626690",false,"NCT07438912","Mind After Midnight","The Mind After Midnight: Mechanistic Examination of Nocturnal Wakefulness as a Suicide Risk Factor","MaM","Inclusion Criteria\n\n* Age 18-55 years\n* History of suicidal ideation within the past 6 months\n* Habitual bedtime between 9:00 PM and 1:00 AM\n* Habitual wake time between 6:00 AM and 9:00 AM\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Current suicidal intent requiring immediate clinical intervention\n* Diagnosis of a primary sleep disorder (e.g., untreated obstructive sleep apnea, narcolepsy)\n* Bipolar disorder or psychotic disorder\n* Substance use disorder within the past 3 months\n* Use of medications that significantly affect sleep or circadian rhythms\n* Night shift work or transmeridian travel within the past month\n* Medical or neurological condition that would interfere with participation\n* Pregnancy","ALL","18 Years","55 Years",{"count":21,"type":22},90,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study examines whether wakefulness during the biological night (2:00-4:00 AM) is associated with increased negative mood, impaired decision-making, and suicidal thoughts. Adults with a history of suicidal ideation in the past six months will complete laboratory and home-based assessments under varying levels of sleep pressure. Participants will be evaluated during late-night wakefulness and under conditions of both higher and lower sleep pressure. The goal of the study is to better understand the biological and behavioral mechanisms that may contribute to elevated suicide risk during nocturnal wakefulness.",[28,29,30,31],"Suicidal Ideation","Circadian Rhythm Disorders","Sleep Deprivation","Sleep Wake Disorders",[33,34,35,36,37,38,39,40],"Nocturnal Wakefulness","Suicide Risk","Circadian Misalignment","Impulsivity","Mood Regulation","Biological Night","Sleep Pressure","Decision-Making","RECRUITING","2026-05-19",{"date":44,"type":45},"2026-05-22","ACTUAL",{"date":47,"type":45},"2026-03-06",{"date":49,"type":22},"2029-08-31",{"name":51,"class":52},"University of Arizona","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":53},"100406886","effects-of-blocking-blue-light-at-night-post-cabg-avr-mvr-cabg-avr-cabg-mvr-or-sah-100406886","NCT04578249","Effects of Blocking Blue Light at Night Post CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH","Effects of Blocking Blue Light at Night on Patient Outcomes After Elective CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH","Inclusion Criteria:\n\n* Both men and women that are undergoing elective (non-emergency)\n\n  * on-pump CABG surgery,\n  * AVR,\n  * MVR,\n  * CABG AVR,\n  * CABG MVR or\n  * SAH\n* No history of diagnosed psychiatric disorders or organ failure\n\nExclusion Criteria:\n\n* Evidence or diagnosis of dementia or other cognitive deficit\n* Diagnosed psychiatric disorder (including depression and anxiety)\n* Organ failure \\[kidney (creatine \\> 1.5 mg\u002FdL), liver, etc.\\]\n* Chronic obstructive pulmonary disease,\n* Any immune disorder\n* Acute infection\n* Prior cardiac surgery\n* Elective aneurysms\n* Combined cardiac operations\n* Left main stenosis greater than 70%\n* Left ventricular ejection fraction (LVEF) lower than 0.5\n* Any condition that increases likelihood of the need for a blood transfusion during or after the surgery\n* Clotting disorder\n* Suspected less than 8th grade English reading comprehension level","45 Years","75 Years",{"count":64,"type":22},80,[25],"Purpose The purpose of this study is to determine whether filtering out blue light at nighttime reduces post-surgical inflammation and\u002For moderates cognitive decline and mood and sleep alterations in patients undergoing elective CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery. If manipulating nighttime light in hospital rooms improves patient outcomes, then it would be a relatively easy and inexpensive innovation that could reduce post-surgical complications and save millions of dollars per year in health care costs by shortening the length of hospital stays and reducing morbidity. The investigators aim to determine the relationship between inflammation and cognitive dysfunction after cardiac surgery.",[29],[69,70,71,72,73,74,75],"CABG","coronary artery bypass graft","light at night","dim light at night","inflammation","cognition","blue light","2026-04-16",{"date":78,"type":45},"2026-04-20",{"date":80,"type":45},"2021-09-20",{"date":82,"type":22},"2027-05",{"name":84,"class":52},"West Virginia University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100626785","effects-of-akkermansia-muciniphila-and-berberine-supplementation-on-insulin-sensitivity-in-night-shift-workers-100626785","NCT07440147","Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers","Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers: a Double-blind, Randomised, Placebo-controlled, Crossover Study Within the Shift2Health Project","Shift2Health","Inclusion Criteria:\n\n* Health care or industrial shift worker\n* Employed or self-employed working ≥ 24 h\u002Fweek\n* Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights\u002Fmonth\n* Night shift work duration \\> 3 years\n* 4 or more night shifts\u002Fmonth\n\nExclusion Criteria:\n\n* BMI of 40 kg\u002Fm² or higher\n* Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women\n* Bariatric surgery\n* Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study\n* Diagnosed diabetes type 1 or type 2\n* Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH\u002FT4 levels without stable medication for more than 3 months)\n* Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)\n* Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable\n* Regular intake of anticoagulants\n* Known allergy to any inactive or active ingredients in the study products\n* Participation in other clinical intervention trials during the study\n* Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)",true,"21 Years",{"count":96,"type":22},200,[25],"Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.\n\nTogether, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.\n\nBased on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.\n\nAssessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.\n\nThe primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.\n\nThese measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.",[100,29,101,102],"Obesity & Overweight","Gut Microbiota Modulation","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","2026-02-23",{"date":105,"type":45},"2026-02-27",{"date":107,"type":45},"2026-01-20",{"date":109,"type":22},"2028-02",{"name":111,"class":112},"FH Joanneum Gesellschaft mbH","INDUSTRY",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":53},"100571991","translation-and-validation-of-the-french-version-of-the-sleep-regularity-questionnaire-a-new-tool-to-address-the-the-challenge-of-sleep-health-100571991","NCT06727448","Translation and Validation of the French Version of the Sleep Regularity Questionnaire: a New Tool to Address the the Challenge of Sleep Health","PRIMO","Inclusion Criteria:\n\n* Patient ≥ 18 years of age\n* Patient with indication for 14-day actimetry for chronic insomnia or circadian rhythm disorder\n* Patients with an indication for 14-day actimetry to assess sleep-wake rhythms, for example prior to a 36-hour polysomnographic recording to diagnose central hypersomnia (narcolepsy or idiopathic hypersomnia).\n* Patient affiliated to or benefiting from a social security scheme\n* Patient with French as mother tongue, able to read and write French.\n* Patient able to understand and complete questionnaires independently\n* Patient informed and not opposed to participating in the study\n\nExclusion Criteria:\n\n* Current psychiatric disorder (mood disorders, anxiety, psychosis, sleep-interfering use disorder) assessed during interview with investigator\n* Current neurological disorder affecting sleep (neurodegenerative disease, stroke, epilepsy) assessed during interview with investigator\n* Unstable cardiovascular or respiratory diseases\n* Pregnant or breast-feeding women\n* Adults under guardianship or curatorship\n* Opposition to participation expressed by healthy patient\u002Fvolunteer",{"count":121,"type":22},50,"OBSERVATIONAL","Sleep is an essential function for physical and mental health. The mismatch between biological rhythms and the social rhythms of individuals is increasingly common in modern societies. This sleep irregularity can have numerous consequences on mental health, cardiometabolic health, the immune system, functioning, and quality of life. To address the public health issue of sleep irregularity, it is important to be able to obtain a valid and reliable measure. The Sleep Regularity Questionnaire (SRQ) by Dzierzewski et al. addresses this issue, but has never been translated into French. The aim of the study is to translate and validate the French version of the Sleep Regularity Questionnaire.",[125,29],"Chronic Insomnia Disorder",[127,128,129,130],"circadian rhythm disorder","Sleep Regularity Questionnaire","SRQ","chronic insomnia disorder","2025-12-09",{"date":133,"type":45},"2025-12-10",{"date":135,"type":45},"2024-12-23",{"date":137,"type":22},"2026-06-23",{"name":139,"class":52},"University Hospital, Bordeaux",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":91,"eligibilityCriteria":146,"healthyVolunteers":93,"sex":17,"minAge":94,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":122,"phases":4,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":53},"100538264","night-shift-work-and-biomarkers-of-obesity-risk-in-hospital-and-industry-workers-100538264","NCT06288568","Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers","Development and Evaluation of Nutritional Strategies to Reduce and Prevent Obesity in Shiftworkers","Inclusion Criteria shift worker\n\n* Health care sector or industrial shift worker\n* Employed or self-employed\n* 21 years or older\n* ≥ 24 h\u002F week\n* Shift work duration \\> 3 years and currently doing night shifts\n* 4 or more rotating night shifts\u002Fmonth (night shift defined as a work schedule that involves working at least 3 hours between 00:00 and 5:00), at least 2 consecutive nights\u002Fmonth\n\nInclusion criteria controls\n\n* Health care sector or industrial work\n* Employed or self-employed\n* 21 years or older\n* ≥ 24 h\u002F week\n* No night shift or rotating shift work in the last 5 years\n* No history of night shift or rotating shift work for more than 5 years\n\nExclusion Criteria shift worker and controls:\n\n* Pregnancy\n* Lactation period\n* BMI of 40 kg\u002Fm2 or above\n* Present treatment of a disease e.g. cancer radio- or chemotherapy\n* Chronic diseases if in an ongoing therapy but not after a remission (renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer)\n* Immunodeficiency syndrome, any auto-immune or auto-inflammatory diseases (e.g. type-1 diabetes, multiple sclerosis, lupus, rheumatoid arthritis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever)\n* Bariatric surgery\n* Antibiotics in the last month",{"count":148,"type":22},1000,"Shift work is a well-known risk factor for the development of overweight and obesity, which may lead to downstream effects such as increased risk of cardiometabolic diseases and cancer. However, the biological and behavioral mechanisms underlying the obesogenicity of night shift work are not well understood. Population-based mechanistic studies in real life shift workers are needed to address how night shift work impacts metabolic health.\n\nThe investigators aim to characterize the behavioural, environmental, and biological mechanisms and pathways for the association of night shift work and obesity across Europe.\n\nThe investigators will conduct a cross sectional study in 5 European countries (Austria, Denmark, Germany, Netherlands and Poland) and recruit 1000 rotating night shift workers and day workers (200\u002Fcountry) from the health sector and different industries. Night and day workers will be age-frequency (3 age groups), gender and (where possible) working tasks matched. Participants will complete online questionnaires and report their diet habits in a mobile app. Body composition, dietary behavior and sensory preferences will be tested. Biologic specimens (blood, urine, saliva, hair and feces) will be collected at the workplace on a day where participants are working on a day shift (or a day off). In a subsample (Austria and Netherlands) shift workers will provide biological samples (spot blood, urine and saliva) both on a day shift and on a night shift. Biomarkers including hormones, cellular immunity and inflammation, parameters linked to gut health and metabolism of fat and sugar, appetite, oxidative stress, metabolomics and microbiota will be measured. The investigators hypothesize that compared to day workers, night shift workers will experience disrupted levels of pre-obesity markers. Higher circadian disruption, sleep disruption and mistimed eating patterns workers will be associated with more disrupted biomarker profiles. Among rotating shift workers, night shift will be associated with acute disrupted melatonin production, metabolomic profiles and composition of oral microbiota compared to a day shift.",[151,152,29],"Obesity","Shift-work Disorder","2025-09-05",{"date":155,"type":45},"2025-09-08",{"date":157,"type":45},"2024-04-01",{"date":159,"type":22},"2028-05-31",{"name":161,"class":52},"University of Vienna",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":169,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100589235","chronotherapeutic-optimization-of-teriparatide-administration-in-postmenopausal-osteoporosis-100589235","NCT06951776","Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis","Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal Osteoporosis: A Randomized Controlled Exploratory Study","Inclusion Criteria:\n\n1. Aged 60-70 years (inclusive).\n2. Naturally postmenopausal women with≥5 years since last menses.\n3. DXA-measured BMD T-score≤-3.0 at lumbar spine (L1-L4) and\u002For total hip at screening.\n4. The concentration of 25-hydroxyvitamin D (25-OH)D is ≥20 ng\u002Fml. If the subject meets all other inclusion and exclusion criteria, it is allowed to retest the 25-OHD concentration after administering vitamin D to the subject.\n5. Normal-range serum parameters:\n\nIntact PTH: 15-65 pg\u002FmL Total calcium: 2.20-2.70 mmol\u002FL.\n\nExclusion Criteria:\n\n1. Subjects with bone metabolic diseases besides osteoporosis:\n\n   1. Other metabolic bone diseases, such as osteomalacia, osteogenesis imperfecta, Paget's disease；\n   2. Cushing's syndrome;\n   3. Hyperprolactinemia;\n2. Use of medications that affect bone metabolism before screening:\n\n   Use of intravenous bisphosphonates, fluoride, or strontium within 2 years; Use of teriparatide or denosumab for osteoporosis within 6 months; Oral bisphosphonates for osteoporosis with the last dose within 1 year (if used within 1 year but with a cumulative use of ≤1 month, the subject is eligible); Continuous use of calcitonin for more than 3 months with the last dose within 1 year.\n3. History of malignancy within 5 years, or bone metastasis, except for tumors that are expected to be cured after treatment (such as completely resected in situ basal cell or squamous cell carcinoma of the skin, cervical cancer, or breast ductal carcinoma, etc.).\n4. Hypocalcemia and hypercalcemia.\n5. Elevated alkaline phosphatase of unknown cause.\n6. History of fractures.\n7. Uncontrolled comorbidities, including heart failure with New York Heart Association (NYHA) functional class III or above, glycated hemoglobin \\>8.5%, and severe arrhythmias.\n8. Allergy to teriparatide.\n9. Currently participating in another drug clinical trial.\n10. Subjects deemed unsuitable for enrollment in this study by the investigator.","FEMALE","60 Years","70 Years",{"count":173,"type":22},28,[25],"This is a randomized, controlled, and exploratory study designed to evaluate the chronotherapeutic effects of teriparatide administration in postmenopausal osteoporosis. Twenty-eight participants (age 60-70 years, lumbar spine T-score ≤-3.0) will undergo 1:1 randomization to receive 20 µg\u002Fday teriparatide subcutaneously at either 08:00 or 20:00 for 12 weeks. Standardized supplementation with calcium (1,000-1,500 mg\u002Fday) and cholecalciferol (800-1,200 IU\u002Fday) will be maintained. Primary endpoints are between-group differences in serum CTX and P1NP profiles, quantified at baseline, 4-week interim, and 12-week endpoint. The secondary outcomes will assess safety during the trial.",[29,177],"Osteoporosis",[179],"Teriparatide, osteoporosis, Chronotherapy","NOT_YET_RECRUITING","2025-04-23",{"date":183,"type":45},"2025-04-30",{"date":185,"type":22},"2025-05-01",{"date":187,"type":22},"2025-12-30",{"name":189,"class":52},"Peking University Third Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":53},"100526069","light-therapy-in-parkinsons-disease-100526069","NCT06129942","Light Therapy in Parkinson's Disease","Light Therapy in Parkinson's Disease: a Prospective, Observational Study","Inclusion Criteria:\n\n* According to the criteria of PD diagnosis of the MDS, PD patients were selected as the research object. The clinical symptoms of PD patients were consistent with Hoehn and Yahr stages 2-3.\n* All PD patients have maintained stable drug treatment for at least one month, signed clinical informed consent and agreed not to adjust drugs throughout the light test and follow-up period.\n\nExclusion Criteria:\n\n* Using hypnotic or stimulating drugs.\n* Using antidepressants, except stable drugs maintained for more than three months;\n* Visual impairment, such as cataract, glaucoma, blindness, etc;\n* Cognitive impairment (MMSE \\\u003C 24);\n* There are uncontrollable hallucinations and mental diseases;\n* There are sleep phase delay \u002F advance syndrome, shift work, jet lag, etc","50 Years","80 Years",{"count":121,"type":22},[25],"The aim of this randomized controlled trial (RCT) is to clarify the effect of bright light therapy on motor symptoms and sleep disorders in patients with Parkinson's disease.",[203,204,29],"Parkinson Disease","Sleep Disorder","2025-02-11",{"date":207,"type":45},"2025-02-12",{"date":209,"type":45},"2021-09-01",{"date":211,"type":22},"2026-05-16",{"name":213,"class":52},"Second Affiliated Hospital of Soochow University"]